Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

What dosage were you prescribed daily?

Have any of the following side effects occurred? (Please check all that apply.)

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Merck & Co. Makes Final Payment to Vioxx Settlement Fund

Mar 2, 2010 | Parker Waichman LLP

Merck & Co. has almost wrapped up its  Vioxx settlement, having recently made its final $4.1 billion payment to the settlement fund.  

According to the Associated Press, all Vioxx heart attack claims have already been paid or denied. Nearly 18,000 Vioxx stroke claims are in process, and about 7,400 of those resulted in initial payments.  The fund should be finished paying all claims by the end of June.

The Associated Press is also reporting about 355 plaintiff groups did not join the settlement. Those lawsuits are still pending. Merck faces four Vioxx lawsuits this year, two bought by patients who didn’t participate in the settlement and two aimed at recovering costs related to use of the painkiller, the Associated Press said.

Vioxx was approved for use in 1999, and quickly became a bestseller for Merck, with annual sales of $2.5 billion; however, the painkiller was pulled off the market in 2004 after an analysis of patients using Vioxx linked the defective drug to more than 27,000 heart attacks or sudden cardiac deaths in the U.S. from 1999 through 2003. The withdrawal prompted thousands of product liability lawsuits that claimed Merck didn’t properly warn doctors and patients of the drug’s risks.

To settle most of those suits, Merck established a $4.85 billion fund in November 2007. Merck set up a $4 billion fund for people who claim they suffered heart attacks as a result of Vioxx, and another $850 million fund for those who suffered ischemic strokes. The settlements were awarded on an individual bases, and the amount of money each plaintiff ultimately receives will vary.

Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo